Multiple analyses compare investment opportunities among leading healthcare companies such as Medtronic, Thermo Fisher, Abbott, Johnson & Johnson, and Danaher. These comparisons focus on aspects like turnaround potential, diversification, growth stories, and recovery prospects.
An article explores whether medical technology company Medtronic (MDT) is on track for a significant business turnaround, analyzing its recent performance and future prospects.
Truist analysts have reiterated a 'Hold' rating on Medtronic (MDT) stock, indicating that the company needs to demonstrate stronger earnings per share growth to warrant a more positive outlook.
An analysis explores whether Medtronic can effectively challenge Intuitive Surgical's long-standing dominance in the market for robotic surgical systems.
Medtronic (MDT) stock has risen by 5.7% following a stellar performance in its fourth quarter. The positive Q4 results have contributed to the company's stock growth.
Greif has announced a 10.7% increase in its dividend to $0.93, while Medtronic plc has raised its dividend by 1.4% to $0.72. These increases reflect positive financial performance and a commitment to shareholder returns from both companies.
This report highlights the leading Wall Street analyst research calls for Thursday, covering companies such as DraftKings, ETSY, GE Healthcare, and more.
Medical technology company Medtronic is set to acquire SPR Therapeutics in a deal valued at around $650 million. The acquisition will expand Medtronic's portfolio in the healthcare sector.
Previews indicate that Medtronic and Donaldson Company are both expected to continue their long-standing dividend growth streaks. Medtronic anticipates extending its streak to 47 years, while Donaldson Company is set to reach 30 years of consecutive dividend increases.
Medtronic (MDT) emphasized the strong momentum of its Affera platform and its recent FDA Breakthrough Device Designation, signaling advancements in its medical technology.
Medical technology company Medtronic has announced that its IT network was subjected to a cyberattack. The company confirmed that despite the incident, its operations have not been disrupted.
Gas prices in the US have eclipsed $4 a gallon, reaching their highest level since 2022 and continuing to rise rapidly, as the Iran war disrupts global energy supply through the Strait of Hormuz.
Medtronic has been cleared to market its new robotic surgical system designed for cranial procedures, expanding its presence in advanced medical technology.
Wednesday's top Wall Street analyst research calls include Cadence Design, Crox, Genuine Parts, Kratos Defense, Medtronic, Palantir, StubHub, Transocean, and more.
Medtronic's cardiovascular and diabetes divisions posted mid-teens growth in the third fiscal quarter, indicating strong performance in these key areas.
Medtronic has successfully completed its first Hugo robotic-assisted surgery in the United States, marking a significant milestone for the company's surgical robotics platform.
Analysis is being conducted to compare Medtronic and Tenet Healthcare for long-term growth potential, and FHLC versus PJP as better healthcare ETF investment options.
An analysis compares Medtronic and Intuitive Surgical, two prominent MedTech stocks, to determine which presents a better investment opportunity currently.
The article examines whether Wall Street analysts hold a bullish or bearish view on Medtronic stock, reflecting their expectations for the medical technology company's performance.
Johnson & Johnson has received FDA approval for its Ottava soft tissue surgical robot. This development has led to a decline in the stock of competitors like Intuitive Surgical and Medtronic.
Leading Wall Street analysts have issued their significant stock recommendations for Thursday, covering major companies such as Nvidia, Apple, Broadcom, and Netflix. These calls provide insights into potential market movements and investment opportunities.
Medtronic received an upgrade from BTIG after reporting better-than-expected financial results for its fiscal year 2026 fourth quarter. The upgrade reflects positive analyst sentiment regarding the company's performance.
Medtronic is actively pursuing acquisitions as a core strategy to drive its growth, indicating a belief that strategic purchases will expand its market presence and capabilities.
Several companies, including IDT Corporation, ChargePoint Holdings, Medtronic, and CrowdStrike, are preparing to release their quarterly earnings reports. Investors are anticipating what to expect from their Q3 2026, Q1 2027, Q4, and Q1 earnings, respectively.
Medtronic has announced plans to establish a new European Software Development Hub in Galway, which is expected to create over 80 jobs. This investment will bolster the company's software capabilities and contribute to local employment.
Medtronic plc (MDT) has announced that its Stealth AXiS™ Surgical System has received the CE Mark, allowing its commercialization in the European market.
Medtronic has successfully concluded its acquisition of CathWorks for $585 million. This strategic move aims to expand Medtronic's portfolio in the medical technology sector.
Mizuho has lowered its target price for Medtronic (MDT) ahead of the company's first-quarter earnings report. Despite the adjustment, Mizuho maintains a positive view on the stock.
This article highlights notable healthcare headlines for the week, focusing on developments related to companies such as Merck, Medtronic, and Novartis.
Medtronic has announced its intention to acquire Scientia Vascular for $550 million, aiming to strengthen its neurovascular business and expand its medical device portfolio.
Medtronic's diabetes business unit, MiniMed, is reportedly planning an Initial Public Offering (IPO) in the United States, aiming to raise $784 million.
Dividend-paying medtech giant Medtronic is highlighted as a company built to survive any market crash, suggesting its resilience in volatile economic conditions.
Several companies, including Parker-Hannifin, Medtronic, Sysco, and Samsung, have announced their latest dividend declarations. These declarations include regular quarterly dividends and, in some cases, special dividends for shareholders.
This article evaluates Johnson & Johnson and Medtronic's stock positions following their recent earnings reports, assessing which healthcare company is better positioned in the market.
An analyst predicts that Medtronic (MDT) stock will experience a significant 40% increase in value by the end of 2026, based on current market analysis.
An analysis evaluates whether Intuitive Surgical or Medtronic is better positioned for growth in the MedTech sector, comparing their stock performance and market outlook.
Hedge funds have identified Medtronic, Charles Schwab, and Berkshire Hathaway as some of the best long-term stocks to buy. These companies are highlighted for their potential to deliver sustained growth and value over an extended period.
BTIG analysts suggest that Medtronic's shares are currently trading at a discount compared to its competitors, making it an opportune time for investment.
Medtronic projects organic revenue growth of 6.75%-7.25% for fiscal year 2027, with an estimated EPS of $5.90-$6.00, despite a $250 million impact from tariffs. The company also reported its strongest annual revenue growth in a decade.
Medtronic announced its Q4 earnings, reporting a non-GAAP EPS of $1.55 and revenue of $9.81 billion, both beating analyst estimates. However, the company's FY26 EPS outlook fell below consensus expectations.
Medtronic reported a strong fourth-quarter beat, with its cardiovascular and diabetes segments continuing their double-digit growth streaks. The company's performance was notably boosted by its cardiovascular division.
Jim Cramer provided his opinions on several company stocks, expressing varied sentiments. He noted that Gap's turnaround isn't progressing as hoped, praised GE Vernova, found Dell's quarter surprising, and commented on the performance of other companies like NVIDIA, Medtronic, and Merck.
Medtronic has announced its intention to acquire SPR, a developer of pain therapy, for $650 million. This acquisition aims to expand Medtronic's offerings in the pain management sector.
An analysis of Medtronic's stock outlook explores whether Wall Street analysts are predominantly bullish or bearish on the company's future performance.
Pulnovo, a medical technology company, has successfully closed a $100 million financing round, which notably includes a strategic investment from Medtronic, bolstering its capital for future development and expansion.
Medtronic plc (MDT) is highlighted for its innovation pipeline and structural changes, which are seen as positive indicators for its stock performance.
A market digest has been released, providing an overview of several key companies including Markel Group Inc., Entergy, FedEx, Gap, Medtronic, Roche Holding AG, and Cleveland-Cliffs.
Medtronic plc (MDT) is reportedly gaining momentum through its diabetes and cardiovascular operations, indicating positive business performance in these sectors.
IDEAYA Biosciences announced its GAAP EPS of -$0.94, beating estimates by $0.03, and reported revenue of $10.88 million, surpassing expectations by $4.93 million.